home / stock / aps:cc / aps:cc news

APS:CC News and Press, Aptose Biosciences Inc. From 03/06/24

Stock Information
Company Name: Aptose Biosciences Inc.
Stock Symbol: APS:CC
Market: TSXC
Website: aptose.com
Menu
APS:CC APS:CC Quote APS:CC Short APS:CC News APS:CC Articles APS:CC Message Board
Get APS:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
APS:CC - Canadian Companies Moving the Markets, Evening edition
Wed, Mar 06, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada Baytex Energy Corp. (BTE) rose 2.7% to $4.305 on volume of 11,390,074 shares Argonaut Gold Inc. (AR) rose 22.0% to $0.305 on volume of 11,228,830 shares Bitfarms Ltd. (BITF) rose 6.2% to $3.58 on volume of 9,336,087 shares Cenovus Energy Inc. ...
APS:CC - Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancie...

APS:CC - Is it Time to Buy the TSX's 3 Worst-Performing Canadian Stocks?

2024-01-26 16:40:00 ET The S&P/TSX Composite Index rose 75 points on Thursday, January 25, 2024. Some of the top-performing sectors included energy, utilities, and battery metals. Today, I want to focus on three of the worst-performing equities to close out 2023. Are these reeling ...

APS:CC - Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, t...
APS:CC - Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Reporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML Patients TUS Single Agent and TUS/VEN Combination Demonstrate Favorable Safety and Tolerability TUS/VEN Combination Active Across Broad P...

APS:CC - Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

SAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...

APS:CC - Aptose Reports Results for the Third Quarter 2023

Tuspetinib (TUS) Targets Venetoclax (VEN) Resistance Mechanisms TUS/VEN Combination Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path, Including FLT3 Mutated and Wildtype TUS/VEN Overall Response Rate of 48% in Heavily Pre-Trea...
APS:CC - Expected Canadian Company Earnings on Thursday, November 9th, 2023

K-Bro Linen Inc. (KBL:CA) is expected to report $0.57 for Q3 2023 Yellow Pages Limited (Y:CA) is expected to report for Q3 2023 Ascot Resources Ltd. (AOT:CA) is expected to report for Q3 2023 Park Lawn Corporation (PLC:CA) is expected to report $0.27 for Q3 2023 Hut 8 Mining Corp....

APS:CC - Expected earnings - Aptose Biosciences Inc.

Aptose Biosciences Inc. (APS:CA) is expected to report $-2.92 for Q3 2023

APS:CC - Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, t...
Previous 10 Next 10